Clinical trials
Completed Phase 2 Proteinuria trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mario Negri Institute for Pharmacological Research | 4 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| AbbVie (prior sponsor, Abbott) | 3 |
| AstraZeneca | 2 |
| Alexandria University | 1 |
| Brigham and Women's Hospital | 1 |
| Calliditas Therapeutics AB | 1 |
| Complexa, Inc. | 1 |
| Ebima Clifford Okundaye | 1 |
| Erling Bjerregaard Pedersen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Proteinuria | 34 |
| Renal Insufficiency, Chronic | 12 |
| Diabetic Nephropathies | 10 |
| Nephrotic Syndrome | 7 |
| Glomerulonephritis | 4 |
| Glomerulosclerosis, Focal Segmental | 4 |
| Kidney Diseases | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Fibrosis | 3 |
| Hypertension | 3 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.